Scott is currently the Corporate SVP and Global Head of Business Development & Licensing at Boehringer Ingelheim, based out of both Ridgefield, CT and Cambridge, MA. He received his BS in Cellular Biology from the University of Connecticut in 1999 and began his research career with Pfizer in Groton, CT. He later earned a PhD in Molecular Biology from the University of North Carolina, and did his postdoc the lab of Nobel Laureate Robert Lefkowitz at Duke University, studying G protein coupled receptor signaling. In late 2007, Scott co-founded a start-up company called Trevena Inc ($TRVN on Nasdaq), helping discover and develop the pain therapy Olinvyk®. After his startup adventure, Scott left Trevena to join BI, initially working in the research group on discovery programs that eventually became the FDA-approved drugs Skyrizi® and Spevigo®. Scott later moved to Business Development, leading Cancer Immunology licensing, and assumed his current role as Global Head of the BD&L team in January of this year.